TOKYO -- The new coronavirus continues to run rampant around the world. The key to controlling the spread of infectious diseases like this is vaccinations that are safe and effective. With more than 200 vaccine candidates, some of which are in the final stages of clinical trials, pharmaceutical giant Pfizer beat its rivals in applying for an emergency use permit in the U.S. Fellow American startup Moderna also plans to file. Here we will explain the race to develop a vaccine that can be put to practical use with visual data.
